Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries

Surgery remains the only curative intent treatment modality for localized pancreatic adenocarcinoma. Even in those who can undergo successful margin negative resection, the ability to deliver adjuvant chemotherapy is suboptimal for various reasons, resulting in poor outcomes. The delivery of standard of care intensive modern neoadjuvant therapies can be challenging in low to-middle-income countries (LMICs) with limited resource. This article reviews the constraints in delivering neoadjuvant therapies in LMICs and strategies to improve its implementation.

Automated summary

Surgery is the only curative treatment for localized pancreatic adenocarcinoma, but delivering adjuvant chemotherapy can be suboptimal in some cases, leading to poor outcomes. Implementing standard neoadjuvant therapies in low to middle-income countries with limited resources may present challenges.